Entero Healthcare Solutions Ltd

The transcript does not explicitly mention current or expected order book or pending orders for Entero Healthcare Solutions Limited. However, based on the discussion: - The company is actively expanding its customer base and geographical reach, suggesting a healthy flow of orders. - They mention servicing large customers with frequent deliveries (2-3 times per day), indicating ongoing strong demand. - The company has a significant product portfolio (87,000 SKUs across 3,000+ companies), which supports continuous order inflow. - Acquisitions have been made to build portfolio and customer base, implying a robust pipeline. - The management highlighted a strong pipeline for acquisitions but did not specify order backlog. - Focus is on improving internal operations and working capital, indicating management is ensuring order fulfillment efficiency. No specific figures on order backlog or pending orders are disclosed in the provided pages.

- The company has broadly completed all big acquisitions as of now. - Currently, there are no plans to raise any equity capital. - There could be some movement in debt, but no indication of significant new debt raising. - The focus for the next few quarters will be on consolidating existing acquisitions, stabilizing operations, improving margins, and cash flows. - Further meaningful acquisitions are not planned immediately; any new fundraising would likely be aligned with future acquisitions after stabilization.

- The business is not capital intensive; most warehouses are leased. - Capex primarily involves storage and cooling equipment with minimal fixed asset base. - To set up one warehouse, capex requirement is approximately INR 30-40 lakhs. - Recent acquisitions might require some capex but overall capex remains minimal relative to revenue. - Next 2-3 quarters, focus will be on integrating recent acquisitions and improving margins rather than new acquisitions. - Capex for FY27 is expected to be lower with more focus on cash generation and integration. - Potential for strategic investments or acquisitions may resume in FY28 after consolidation. - Private labels and scaling up in home healthcare may involve future investments but currently remain small. Overall, incremental capex is low, mostly maintenance-related, aligned with leasing model and growth through acquisitions rather than heavy capital investments.

- Organic growth estimated at 1.5x industry growth; sustainable growth expected beyond acquisitions. - FY27 growth to be better than FY26 due to full-year impact of H2 FY26 acquisitions plus organic growth. - Next year’s growth driven by acquisition impact and organic expansion, with no material slowdown anticipated. - MedTech segment seen as a large growth opportunity with potential for faster growth due to pan-India exclusive distribution deals. - Existing warehouse infrastructure and relationships with pharma companies provide leverage for further growth. - Continuous expansion through acquiring companies that add unique geographies or product segments. - Focus on wallet share increase in existing customers and cross-selling to newly acquired customers. - Portfolio expansion with ~87,000 SKUs and over 3,000 companies supports wide market reach. - Retailers benefit from large consolidated product offerings and frequent deliveries, enhancing stickiness and growth.

- FY27 expected to be far better than FY26, driven by full-year impact of acquisitions made in FY26 and organic growth (Page 14). - Operating cash flow (OCF) for FY26 targeted at INR100 crores, requiring strong positive cash flow in Q4; full-year cash flow projections maintained (Pages 18, 10). - EBITDA margin guidance maintained at 4% for FY26 with expectation to cross 4.5% in Q4 (Page 10). - MedTech segment acquisitions expected to improve gross margin by 70-90 basis points and EBITDA margin by 50-75 basis points on a pro forma basis (Page 8). - Longer-term organic growth levers include increasing wallet share, cross-selling acquired customers, and offering a vast product portfolio, supporting 1.5x industry growth rate sustainably (Page 15). - Growth for FY27 will come from organic growth plus acquisition impact from FY26; acquisition plans for FY27 are limited to consolidation (Page 14). - Confident on maintaining faster than industry revenue growth and margin expansion with robust last-mile distribution and new segment capabilities (Pages 3, 9).